Literature DB >> 9189124

Technetium-99m-tetrofosmin for parathyroid scintigraphy: a comparison with sestamibi.

J G Fjeld1, K Erichsen, P F Pfeffer, O P Clausen, K Rootwelt.   

Abstract

UNLABELLED: Parathyroid scintigraphy with the new myocardial perfusion radiopharmaceutical 99mTc-tetrofosmin was compared with 99mTc-sestamibi scintigraphy using early and delayed imaging.
METHODS: The two preparations were administered on different days to the same 16 patients suffering from primary hyperparathyroidism. Anterior view gamma camera planar imaging (10-min acquisition) was performed in the period between 5 min and 3 hr after administration of the radiopharmaceutical. For most of the patients, a pertechnetate image of the thyroid was available for eyeball comparison when reading the tetrofosmin and sestamibi images. Imaging results were compared with those from histopathological examination after surgery.
RESULTS: On early images, all the adenomas visualized with sestamibi were equally well seen with tetrofosmin and vice versa. In 6 of 11 scintigraphically detected neck adenomas, delayed imaging improved the adenoma visualization with sestamibi. In contrast, this differential washout was never seen with tetrofosmin. Histopathological examination of excised tissue specimens after neck exploration (15 patients) or thoracotomy (one patient) revealed a parathyroid adenoma in all 16 patients. Our 12 scintigraphic findings were true-positives, while the remaining four scintigraphies were false-negatives, giving a diagnostic sensitivity of 75% with both preparations. The mediastinal adenoma was detected in a patient with a history of two unsuccessful neck explorations and one unsuccessful thoracotomy.
CONCLUSION: Tetrofosmin has the same success rate as sestamibi for detection of parathyroid adenomas on scintigrams acquired immediately after injection. In contrast to sestamibi, delayed imaging has no diagnostic impact. Moreover, the thyroid/ parathyroid differential washout of sestamibi failed in 5 of 11 neck adenomas here detected, indicating that delayed sestamibi washout is an unreliable diagnostic criterion. Therefore, whether sestamibi or tetrofosmin is preferred for parathyroid scintigraphy, thyroid scintigraphy seems mandatory.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9189124

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  6 in total

1.  11C-methionine PET versus 99mTc-sestamibi in the pre-operative localisation of hyperfunctional parathyroid tissue.

Authors:  Theodoros Athanasoulis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

2.  Brain tumor imaging with 99mTc-tetrofosmin: comparison with 201Tl, 99mTc-MIBI, and 18F-fluorodeoxyglucose.

Authors:  J Y Choi; S E Kim; H J Shin; B T Kim; J H Kim
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

3.  The value of Tc-99m tetrofosmin in the imaging of pituitary adenomas.

Authors:  N Kurtulmus; C Turkmen; S Yarman; H Tokmak; A Mudun
Journal:  J Endocrinol Invest       Date:  2007-02       Impact factor: 4.256

4.  Primary hyperparathyroidism: imaging to pathology.

Authors:  Sara Piciucchi; Domenico Barone; Giampaolo Gavelli; Alessandra Dubini; Devil Oboldi; Federica Matteuci
Journal:  J Clin Imaging Sci       Date:  2012-10-06

5.  Sensitivity and Specificity of Dual-Isotope 99mTc-Tetrofosmin and 123I Sodium Iodide Single Photon Emission Computed Tomography (SPECT) in Hyperparathyroidism.

Authors:  Michael Sommerauer; Carmen Graf; Niklaus Schäfer; Gerhard Huber; Paul Schneider; Rudolf Wüthrich; Christoph Schmid; Hans Steinert
Journal:  PLoS One       Date:  2015-06-16       Impact factor: 3.240

6.  2009 EANM parathyroid guidelines.

Authors:  Elif Hindié; Omer Ugur; David Fuster; Michael O'Doherty; Gaia Grassetto; Pablo Ureña; Andrew Kettle; Seza A Gulec; Francesca Pons; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-07       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.